Trilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer’s Disease Mouse Model

Alzheimer’s disease (AD) is the most common neurodegenerative disease nowadays that causes memory impairments. It is characterized by extracellular aggregates of amyloid-beta (Aβ), intracellular aggregates of hyperphosphorylated Tau (p-Tau), and other pathological features. Trilobatin (TLB), a natur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiuyang Ding, Jian Huang, Dan Yin, Ting Liu, Zheng Ren, Shanshan Hu, Yuanliang Ye, Cuiyun Le, Na Zhao, Hongmei Zhou, Zhu Li, Xiaolan Qi, Jiang Huang
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Cytology QH573-671
Acceso en línea:	https://doaj.org/article/33291114d8c740ab9896d7adb633d980
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:33291114d8c740ab9896d7adb633d980
record_format	dspace
spelling	oai:doaj.org-article:33291114d8c740ab9896d7adb633d9802021-11-15T01:20:00ZTrilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer’s Disease Mouse Model1942-099410.1155/2021/3298400https://doaj.org/article/33291114d8c740ab9896d7adb633d9802021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/3298400https://doaj.org/toc/1942-0994Alzheimer’s disease (AD) is the most common neurodegenerative disease nowadays that causes memory impairments. It is characterized by extracellular aggregates of amyloid-beta (Aβ), intracellular aggregates of hyperphosphorylated Tau (p-Tau), and other pathological features. Trilobatin (TLB), a natural flavonoid compound isolated from Lithocarpuspolystachyus Rehd., has emerged as a neuroprotective agent. However, the effects and mechanisms of TLB on Alzheimer’s disease (AD) remain unclear. In this research, different doses of TLB were orally introduced to 3×FAD AD model mice. The pathology, memory performance, and Toll-like receptor 4- (TLR4-) dependent inflammatory pathway protein level were assessed. Here, we show that TLB oral treatment protected 3×FAD AD model mice against the Aβ burden, neuroinflammation, Tau hyperphosphorylation, synaptic degeneration, hippocampal neuronal loss, and memory impairment. The TLR4, a pattern recognition immune receptor, has been implicated in neurodegenerative disease-related neuroinflammation. We found that TLB suppressed glial activation by inhibiting the TLR4-MYD88-NFκB pathway, which leads to the inflammatory factor TNF-α, IL-1β, and IL-6 reduction. Our study shows that TLR4 might be a key target of TLB in AD treatment and suggests a multifaceted target of TLB in halting AD. Taken together, our findings suggest a potential therapeutic effect of TLB in AD treatment.Jiuyang DingJian HuangDan YinTing LiuZheng RenShanshan HuYuanliang YeCuiyun LeNa ZhaoHongmei ZhouZhu LiXiaolan QiJiang HuangHindawi LimitedarticleCytologyQH573-671ENOxidative Medicine and Cellular Longevity, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cytology QH573-671
spellingShingle	Cytology QH573-671 Jiuyang Ding Jian Huang Dan Yin Ting Liu Zheng Ren Shanshan Hu Yuanliang Ye Cuiyun Le Na Zhao Hongmei Zhou Zhu Li Xiaolan Qi Jiang Huang Trilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer’s Disease Mouse Model
description	Alzheimer’s disease (AD) is the most common neurodegenerative disease nowadays that causes memory impairments. It is characterized by extracellular aggregates of amyloid-beta (Aβ), intracellular aggregates of hyperphosphorylated Tau (p-Tau), and other pathological features. Trilobatin (TLB), a natural flavonoid compound isolated from Lithocarpuspolystachyus Rehd., has emerged as a neuroprotective agent. However, the effects and mechanisms of TLB on Alzheimer’s disease (AD) remain unclear. In this research, different doses of TLB were orally introduced to 3×FAD AD model mice. The pathology, memory performance, and Toll-like receptor 4- (TLR4-) dependent inflammatory pathway protein level were assessed. Here, we show that TLB oral treatment protected 3×FAD AD model mice against the Aβ burden, neuroinflammation, Tau hyperphosphorylation, synaptic degeneration, hippocampal neuronal loss, and memory impairment. The TLR4, a pattern recognition immune receptor, has been implicated in neurodegenerative disease-related neuroinflammation. We found that TLB suppressed glial activation by inhibiting the TLR4-MYD88-NFκB pathway, which leads to the inflammatory factor TNF-α, IL-1β, and IL-6 reduction. Our study shows that TLR4 might be a key target of TLB in AD treatment and suggests a multifaceted target of TLB in halting AD. Taken together, our findings suggest a potential therapeutic effect of TLB in AD treatment.
format	article
author	Jiuyang Ding Jian Huang Dan Yin Ting Liu Zheng Ren Shanshan Hu Yuanliang Ye Cuiyun Le Na Zhao Hongmei Zhou Zhu Li Xiaolan Qi Jiang Huang
author_facet	Jiuyang Ding Jian Huang Dan Yin Ting Liu Zheng Ren Shanshan Hu Yuanliang Ye Cuiyun Le Na Zhao Hongmei Zhou Zhu Li Xiaolan Qi Jiang Huang
author_sort	Jiuyang Ding
title	Trilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer’s Disease Mouse Model
title_short	Trilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer’s Disease Mouse Model
title_full	Trilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer’s Disease Mouse Model
title_fullStr	Trilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer’s Disease Mouse Model
title_full_unstemmed	Trilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer’s Disease Mouse Model
title_sort	trilobatin alleviates cognitive deficits and pathologies in an alzheimer’s disease mouse model
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/33291114d8c740ab9896d7adb633d980
work_keys_str_mv	AT jiuyangding trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel AT jianhuang trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel AT danyin trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel AT tingliu trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel AT zhengren trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel AT shanshanhu trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel AT yuanliangye trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel AT cuiyunle trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel AT nazhao trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel AT hongmeizhou trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel AT zhuli trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel AT xiaolanqi trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel AT jianghuang trilobatinalleviatescognitivedeficitsandpathologiesinanalzheimersdiseasemousemodel
_version_	1718428915106578432

Trilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer’s Disease Mouse Model

Ejemplares similares